Authors:
SPRIET A
CHAUMETRIFFAUD P
ALLARD M
BILLARDON M
CATTELIN F
CHILDS M
DELACOURTE M
DELALLEAU B
DIGIAMBERARDINO L
EMRE M
GENTHON R
GONI S
JAFFARD R
LACOMBLEZ L
LEBERT F
LEGER JM
MAHIEUX F
MICHEL B
PARTIOT A
PASQUIER F
PAUL HPS
PUECH A
REIGNEAU O
RENAULT S
SCHLENCK A
Citation: A. Spriet et al., ESSENTIAL ELEMENTS OF QUALITY ASSURANCE O F CLINICAL-TRIALS IN-HOSPITAL SETTING, Therapie, 51(4), 1996, pp. 434-438
Authors:
DUBOIS B
STEHLE B
LEHNER JP
DEROUESNE C
BOURIN M
LAMOUR Y
BLIN O
JOURDAIN G
ALPEROVITCH A
ALLARD M
BILLARDON M
CATTELIN F
CHILDS M
DELACOURTE M
DELALLEAU B
DIGIAMBERARDINO L
EMRE M
GENTHON R
GONI S
JAFFARD R
LACOMBLEZ L
LEBERT F
LEGER JM
MAHIEUX F
MICHEL B
PARTIOT A
PASQUIER F
PAUL HPS
PUECH A
REIGNEAU O
RENAULT S
SCHLENCK A
Citation: B. Dubois et al., METHODOLOGY FOR DEVELOPING DRUGS IN ALZHE IMER-DISEASE, Therapie, 51(4), 1996, pp. 444-448
Authors:
KAMOUN A
DELALLEAU B
GOUGOULIS N
RICHARD A
SALVADORI C
Citation: A. Kamoun et al., ANTIDEPRESSANT EFFECT OF TIANEPTINE - RECENT CLINICAL-TRIALS IN SUPPORT OF A NEUROCHEMICAL PARADOX, The European journal of psychiatry, 8(3), 1994, pp. 163-177